Corporate Profile

CalciMedica is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of CRAC channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies.

Learn More

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Featured Events

View all Events

Featured Reports

View all Reports

Press Releases

13 May 24

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Last patient enrolled in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); topline data expected in 2Q 2024 KOURAGE, Phase 2 trial in severe acute kidney injury (AKI) remains on track to initiate patient enrollment in 2Q 2024 with data expected in 2025 Collaborators from Cedars-Sinai to
07 May 24

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

Collaborators from Cedars-Sinai to present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis (AP) LA JOLLA, Calif. , May 7, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on
24 Apr 24

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Full target enrollment of 216 patients achieved  Topline data from CARPO expected in 2Q 2024   LA JOLLA, Calif. , April 24, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated
28 Mar 24

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Enrollment in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP), on track with topline data expected in 2Q 2024   Auxora granted Investigational New Drug clearance by the FDA for Phase 2 trial in severe acute kidney injury (AKI); KOURAGE initiating in 2Q 2024 CRSPA Phase 1/2 trial of
View all Releases
Explore More
Our Technologies
Our Pipeline
Our Story
Our Team